Literature DB >> 8425535

Human and rodent Alzheimer beta-amyloid peptides acquire distinct conformations in membrane-mimicking solvents.

L Otvos1, G I Szendrei, V M Lee, H H Mantsch.   

Abstract

The major constituent of senile plaques (one of the hallmark lesions of Alzheimer's disease) is a 42(43)-amino-acid polypeptide, termed the A4 or beta-amyloid peptide. The beta-amyloid peptide or A4 is derived from one or more larger beta-amyloid precursor proteins. The precursor protein from whence the A4 peptide is derived is highly conserved throughout evolution, and humans, monkeys, dogs, and bears develop brain deposits of A4 peptide in amyloid fibrils. However, similar accumulations of A4 amyloid are negligible in the brains of rats and mice for reasons that remain unexplored. Notably, the A4 sequence of rodents, deduced from the cDNA clones, differs only in three amino acids from the A4 isolated from the brain of humans. Hence, these differences could account for the inability of rodents to develop Alzheimer-like A4 amyloid plaques. To test this hypothesis directly, using physical and chemical model systems, we synthesized, purified, and characterized A4 peptides corresponding to the human and rodent sequences. Circular dichroic and Fourier-transform infrared spectroscopy were used with various membrane-mimicking solvents, different peptide concentrations, and variable pH to identify those environmental conditions that promoted beta-pleated sheet formation of the human versus rodent A4. At an intermediate alkaline pH (< or = 10), the rodent peptide has more beta-pleated sheet structure than the human sequence. The beta-pleated sheets for both peptides could be eliminated at very high pH (> or = 12). The amount of the beta-structure increased in an octyl glucoside solution, compared to that found in SDS, as well as in several of the other solutions tested here. This suggests that particles originated from prior membrane damage may play a role in the stabilization of beta-pleated sheets with subsequent formation of amyloid deposits. Finally, we found that higher beta-pleated sheet content was observed for the rodent sequences in acetonitrile/water mixtures. In contrast, more beta-pleated sheets were detected with the human A4 in trifluoroethanol/water mixtures at neutral pH. Remarkably, at relatively low peptide concentrations, only the human sequences assumed an extended secondary structure. These data suggest that subtle inter-species amino-acid differences may account for the inability of the rodent peptide to form amyloid fibrils in situ.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8425535     DOI: 10.1111/j.1432-1033.1993.tb19893.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  21 in total

1.  Role of Species-Specific Primary Structure Differences in Aβ42 Assembly and Neurotoxicity.

Authors:  Robin Roychaudhuri; Xueyun Zheng; Aleksey Lomakin; Panchanan Maiti; Margaret M Condron; George B Benedek; Gal Bitan; Michael T Bowers; David B Teplow
Journal:  ACS Chem Neurosci       Date:  2015-10-19       Impact factor: 4.418

2.  Exogenous seeding of cerebral β-amyloid deposition in βAPP-transgenic rats.

Authors:  Rebecca F Rosen; Jason J Fritz; Jeromy Dooyema; Amarallys F Cintron; Tsuyoshi Hamaguchi; James J Lah; Harry LeVine; Mathias Jucker; Lary C Walker
Journal:  J Neurochem       Date:  2011-11-18       Impact factor: 5.372

3.  In situ characterization of beta-amyloid in Alzheimer's diseased tissue by synchrotron Fourier transform infrared microspectroscopy.

Authors:  L P Choo; D L Wetzel; W C Halliday; M Jackson; S M LeVine; H H Mantsch
Journal:  Biophys J       Date:  1996-10       Impact factor: 4.033

Review 4.  Guinea pigs as a nontransgenic model for APP processing in vitro and in vivo.

Authors:  Mike Beck; Volker Bigl; Steffen Rossner
Journal:  Neurochem Res       Date:  2003-04       Impact factor: 3.996

5.  Disruption of prion rods generates 10-nm spherical particles having high alpha-helical content and lacking scrapie infectivity.

Authors:  D Riesner; K Kellings; K Post; H Wille; H Serban; D Groth; M A Baldwin; S B Prusiner
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

6.  Experimental traumatic brain injury induces rapid aggregation and oligomerization of amyloid-beta in an Alzheimer's disease mouse model.

Authors:  Patricia M Washington; Nicholas Morffy; Maia Parsadanian; David N Zapple; Mark P Burns
Journal:  J Neurotrauma       Date:  2013-12-10       Impact factor: 5.269

Review 7.  The toxicity in vitro of beta-amyloid protein.

Authors:  L L Iversen; R J Mortishire-Smith; S J Pollack; M S Shearman
Journal:  Biochem J       Date:  1995-10-01       Impact factor: 3.857

8.  Alzheimer's presenilin mutation sensitizes neural cells to apoptosis induced by trophic factor withdrawal and amyloid beta-peptide: involvement of calcium and oxyradicals.

Authors:  Q Guo; B L Sopher; K Furukawa; D G Pham; N Robinson; G M Martin; M P Mattson
Journal:  J Neurosci       Date:  1997-06-01       Impact factor: 6.167

Review 9.  Glial Na(+) -dependent ion transporters in pathophysiological conditions.

Authors:  Francesca Boscia; Gulnaz Begum; Giuseppe Pignataro; Rossana Sirabella; Ornella Cuomo; Antonella Casamassa; Dandan Sun; Lucio Annunziato
Journal:  Glia       Date:  2016-07-26       Impact factor: 7.452

10.  PIB binding in aged primate brain: enrichment of high-affinity sites in humans with Alzheimer's disease.

Authors:  Rebecca F Rosen; Lary C Walker; Harry Levine
Journal:  Neurobiol Aging       Date:  2009-03-28       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.